PharmaResearch said Friday that its polynucleotide (PN)-based medical device, Rejuran HB Plus, has won approval from the Ministry of Food and Drug Safety and plans to begin marketing from the second half of the year.

PharmaResearch plans to begin supplying its skin booster Rejuran HB Plus from the second half of the year as the product has won regulatory approval.
PharmaResearch plans to begin supplying its skin booster Rejuran HB Plus from the second half of the year as the product has won regulatory approval.

The company has upgraded Rejuran HB Plus by adding hyaluronic acid (HA) and lidocaine to the existing PN ingredient. As a result, Rejuran HB Plus inflicts relatively less pain due to lidocaine and shows enhanced efficacy with HA.

Rejuran®HB Plus improves wrinkles at the outer corners of the eyes, which is known as the crow’s feet, by subcutaneously injecting PN and HA around the affected area.

PharmaResearch has improved its aesthetics portfolio with Rejuran HB Plus on top of Rejuran, Rejumate Injector, botulinum toxin “Re N Tox,” and dermal filler Rejuviel.

“Patients can expect satisfying outcomes from Rejuran HB Plus with less pain compared to the existing Rejuran series,” a PharmaResearch official said. “We are planning to begin marketing Rejuran HB Plus in the second half of 2021.”

In addition to the company’s anticipated launch of Rejuran HB Plus, it also has been manufacturing and supplying pharmaceuticals, medical devices, cosmetics, and functional foods based on the core strength in regenerative medicines, including DOT PDRN and DOT PN.

Besides, PharmaResearch holds many products, such as Rejuran, Conjuran, Rejuran Cosmetic, and Re-An Eye drop, that highlight the company’s focus on regenerative medicines.

Copyright © KBR Unauthorized reproduction, redistribution prohibited